Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/30/2024 | $15.00 | Buy | H.C. Wainwright |
| 8/22/2024 | $16.00 | Buy | Rodman & Renshaw |
| 3/7/2024 | $5.00 | Hold → Buy | The Benchmark Company |
| 11/20/2023 | Underweight | JP Morgan | |
| 8/29/2023 | Buy → Hold | The Benchmark Company | |
| 4/10/2023 | $22.00 | Hold → Buy | The Benchmark Company |
| 3/17/2023 | $23.00 → $9.00 | Neutral → Underweight | JP Morgan |
| 11/10/2022 | Buy → Hold | The Benchmark Company |
GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000® vaccine and ancillary products to more than $120 million this year from a diverse base of customers. ACAM2000® is licensed for active immunization against smallpox and mpox disease for persons determined to be at high risk for smallpox or mpox infection. "Our new contract modification for ACAM2000® vaccine reflects the conti
GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar year and are scheduled to be completed by March 2026. "This new contract modification is the next step in our ongoing engagement with the U.S. government, with the shared goal to help ensure medical countermeasures, like
Pro Football Hall of Famer and Ready to Rescue campaign spokesperson, Emmitt Smith, and Release Recovery Founder/CEO, Zac Clark, plan to visit several U.S. college campuses to educate on opioid emergency preparednessNew sponsorship of Mobilize Recovery's "Campus Surge" initiative brings addiction prevention and recovery support to higher education institutions GAITHERSBURG, Md., Aug. 29, 2025 (GLOBE NEWSWIRE) -- In honor of International Overdose Awareness Day (IOAD) on August 31, Emergent BioSolutions (NYSE:EBS) is re-launching its Ready to Rescue public education campaign, which raises awareness of opioid emergencies and the importance of being prepared with NARCAN® Nasal Spray among
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00
The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
EFFECT - Emergent BioSolutions Inc. (0001367644) (Filer)
144 - Emergent BioSolutions Inc. (0001367644) (Subject)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an
Ongoing support of the ‘White House Challenge to Save Lives from Overdose' through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emerg
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro
SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
Second Quarter 2025 Total Revenues of $140.9 million, above Q2 guidance by $21 millionSecond Quarter 2025 Net Loss of $12.0 million and Net Loss Margin of (9)%, an improvement of 96% and 10,200 bps, respectively, versus prior yearSecond Quarter 2025 Gross Margin % of 36% and Adjusted Gross Margin % of 49%, an expansion of 6,200 bps and 2,300 bps, respectively, versus prior yearSecond Quarter 2025 Adjusted EBITDA of $28.5 million, an increase of 382% versus prior yearSecond Quarter 2025 Adjusted EBITDA Margin of 20% of Total Revenues, an improvement of 2,400 bps versus prior yearRaising the low end/midpoint of Full Year 2025 Profitability Guidance GAITHERSBURG, Md., Aug. 06, 2025 (GLOBE NE
GAITHERSBURG, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, August 6, 2025, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can be
First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior yearFirst Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior yearFirst Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 500 bps and 700 bps, respectively, versus prior yearFirst Quarter 2025 Adjusted EBITDA of $77.6 million, increase of 16% versus prior yearFirst Quarter 2025 Adjusted EBITDA Margin of 35% of Total Revenues, an improvement of 1,300 bps versus prior yearReaffirmed FY 2025 Guidance GAITHERSBURG, Md., May 07, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results for the first quarter ended March